SecBot SecBot

PLX

Protalix BioTherapeutics, Inc.
NYSE· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001006281 Biotech & Drug Discovery
$3.03 −0.02 (−0.66%)
Nov 16 4:00 PM ET · prev $3.05
Market cap
$249.2M
Micro cap
Consensus
Buy
80% Buy or better · 5 analysts
Median target
$12.00
+296% · range $12.00–12.00
1 year
+60.3%
from $1.89 · Nov 17
30 days
+18.4%
from $2.56
52-week range
$1.67–3.15
−4% from high · low Dec 2
Avg volume 20D
974.5K
Nov 11 spike 3.09M
Short interest
3.48M
≈4.3% of shares · −0.8%
Days to cover
6.2
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
3
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/2

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q3 2026: 15 added (0 new), 10 trimmed or exited.

  • AnalystsBULLISH

    4 of 5 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.010 → −$0.020 over 90 days.

  • Short sellersSTEADY

    Short interest −0.8% to 3.48M shares. 6.2 days to cover, ≈4.3% of shares.

  • TrendUPTREND

    12% above its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
DIMENSIONAL FUND ADVISORS LPADD716,986$2.0M
MARSHALL WACE, LLPTRIM301,768$832.9K
Russell Investments Group, Ltd.DOUBLED248,557$686.0K
MORGAN STANLEYADD97,585$269.3K
Walleye Capital LLCDOUBLED70,533$194.7K
JPMORGAN CHASE & COTRIM40,133$108.0K
BARCLAYS PLCDOUBLED31,938$88.1K
BNP PARIBAS FINANCIAL MARKETSADD20,730$57.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

5 analysts
Buy 80% rate it Buy or better
Strong Buy1Buy3Hold1Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +296%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Sep 9, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 3, 2026
Boudes Pol F
Director
Sep 3, 2026
AWARD8,500 sh
Sep 3, 2026
Boudes Pol F
Director
Sep 3, 2026
AWARD17,000 sh
Sep 3, 2026
Bashan Dror
PRESIDENT AND CEO
Sep 3, 2026
AWARD160,000 sh
Sep 3, 2026
Bashan Dror
PRESIDENT AND CEO
Sep 3, 2026
AWARD320,000 sh
Sep 3, 2026
Elze Christian
Director
Sep 3, 2026
AWARD8,500 sh
Sep 3, 2026
Elze Christian
Director
Sep 3, 2026
AWARD17,000 sh
Sep 3, 2026
Naos Yaron
Sr. VP & COO
Sep 3, 2026
AWARD56,000 sh
Sep 3, 2026
Ben Zvi Shmuel
Director
Sep 3, 2026
AWARD8,500 sh

Earnings setup

Estimates
−$0.02
EPS estimate, this quarter
−100%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.02-$0.04–$0.01-100.0%$12.9M
Next Q$0.01$0.01–$0.01+0.0%$15.8M
Current FY🔒 Fresh data, subscribers only
Next FYNoneNoneNo data$76.3M

Short side

FINRA· Oct 30, 2026
3,480,033
shares short
-0.8%
vs prior settlement
6.2
days to cover
≈4.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 10, 2026 SEC
Protalix reported Q3 2026 total revenue of $21.9M, up 22.8% YoY from $17.9M, and net income of $4.0M ($0.05 per share)…
8-K · Impact 4/10
Nov 10, 2026 Earnings result
PLX Q3 2026 Earnings: EPS $0.05 (+265.0% vs est)
Oct 15, 2026 SEC
HOLD Alapkezelo Zrt., a Hungarian investment fund management company, filed a Schedule 13G disclosing a passive 5.2%…
SC 13G · Impact 3/10
Sep 30, 2026 Inst.
DIMENSIONAL FUND ADVISORS LP · ADD
716,986 shares ($2.0M)
Sep 30, 2026 Inst.
MARSHALL WACE, LLP · TRIM
301,768 shares ($832.9K)
Sep 3, 2026 Insider
Boudes Pol F was granted 8,500 shares
Director
Sep 3, 2026 Insider
Boudes Pol F was granted 17,000 shares
Director
Sep 3, 2026 Insider
Bashan Dror was granted 160,000 shares
PRESIDENT AND CEO
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
4 drugs tracked · Drug pipeline →
Recent

SecBot reports

3 filings · 0 bullish · 0 bearish · 3 neutral
All PLX filing & press-release reports (3)